Raymond James Upgraded This Biopharma Stock And Sees 44% Upside

  • Raymond James has upgraded NGM Biopharmaceuticals Inc NGM to Strong Buy from Outperform with a price target of $39, up from $27, almost 44% upside.
  • Analyst Steven Seedhouse notes the validation of NGM's C3 antibody mechanism and the large potential opportunity for NGM621 in geographic atrophy (GA). 
  • Seedhouse writes that Phase 3 data for Apellis Pharmaceuticals Inc's APLS pegcetacoplan in GA provide strong evidence that complement inhibition is an active mechanism in GA. 
  • Related Content: Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line.
  • The update makes the large GA market accessible to the few mid-stage clinical complement players with plenty of room for differentiation/optimization, he contends. 
  • Near term, the first-look readout for cancer cachexia agent NGM120 at ESMO next week is a free call option, Seedhouse adds.
  • Price Action: NGM stock is up 13% at $26.39 during the market session on the last check Monday.
Loading...
Loading...
APLS Logo
APLSApellis Pharmaceuticals Inc
$17.17-3.43%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
9.40
Growth
Not Available
Quality
Not Available
Value
46.95
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...